argenx SE (ARGX) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Argenx Is Maintained at Outperform by Evercore ISI Group
Dow JonesNov 21 08:43 ET · Ratings
Evercore Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $706
Moomoo NewsNov 21 08:31 ET · Ratings
Oppenheimer Maintains Argenx SE(ARGX.US) With Buy Rating, Raises Target Price to $675
Moomoo NewsNov 21 08:31 ET · Ratings
Jefferies Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $689
Moomoo NewsNov 21 08:31 ET · Ratings
Jefferies Sticks to Their Buy Rating for Argenx Se (ARGX)
TipRanksNov 21 08:16 ET · Ratings
A Quick Look at Today's Ratings for Argenx SE(ARGX.US), With a Forecast Between $606 to $770
Moomoo NewsNov 21 08:00 ET · Ratings

Comments

Money Thrill

Nov 12 03:38

European Morning news [MarketDevil]

$argenx SE (ARGX.US)$ (ABM FN) China's regulator has approved the Supplemental Biologics License Application for Vyvgart Hytrulo for the treatment of adults suffering from CIDP. The biotech company announced this after the close.
This approval followed the Adhere study.This concerns an injection of 1,000 milligrams that can be administered once a week. About 50,000 people in China suffer from CIDP.
“It is the first and only treatment approved in China for CIDP,”...

Money Thrill

Nov 2 14:19

European News from journal HLN (LeatestNewsJournal)

$argenx SE (ARGX.US)$ Last quarter, the company recorded a net profit of 91.4 million euros, compared to a net loss of 72.6 million euros in the same period last year. After nine months there is a net profit of 58.9 million euros against a net loss of 195.9 million euros.
The difference between the operational results and the net result is mainly made up of the financial results and the taxes on the result. At the end of September, Argenx still h...

1

Meltyy

Jun 25 07:02

🔔 FDA PDUFA Update…

🔥 3 PDUFA decisions this week! 👇
📌 This week’s PDUFAs:
$Merck & Co (MRK.US)$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma (VRNA.US)$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab (GMAB.US)$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co (MRK.US)$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...